CoChat

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Open access

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

Background Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a programmed cell death 1 ligand 1 (PD-L1) inhibitor, atezolizumab, in patients with solid tumors.Patients and methods This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. In most patients, cobimetinib was dosed once daily orally for 21 days on, 7 days off. Atezolizumab was dosed at 800 mg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary end points included objective response rate, progression-free survival, and overall survival.Results Between 27 December 2013 and 9 May 2016, 152 patients were enrolled. As of 4 September 2017, 150 patients received ≥1 dose of atezolizumab, including 14 in the dose-escalation cohorts and 136 in the dose-expansion cohorts. Patients had metastatic colorectal cancer (mCRC; n = 84), melanoma (n = 22), non-small-cell lung cancer (NSCLC; n = 28), and other solid tumors (n = 16). The most common all-grade treatment-related adverse events (AEs) were diarrhea (67%), rash (48%), and fatigue (40%), similar to those with single-agent cobimetinib and atezolizumab. One (<1%) treatment-related grade 5 AE occurred (sepsis). Forty-five (30%) and 23 patients (15%) had AEs that led to discontinuation of cobimetinib and atezolizumab, respectively. Confirmed responses were observed in 7 of 84 patients (8%) with mCRC (6 responders were microsatellite low/stable, 1 was microsatellite instable), 9 of 22 patients (41%) with melanoma, and 5 of 28 patients (18%) with NSCLC. Clinical activity was independent of KRAS/BRAF status across diseases.Conclusions Atezolizumab plus cobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status. Although potential synergistic activity was seen in mCRC, this was not confirmed in a subsequent phase III study.Clinicaltrials.gov identifier NCT01988896 (the investigators in the NCT01988896 study are listed in the supplementary Appendix, available at Annals of Oncology online).

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz113

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Cited by

See all 174

Metadata

Authors
Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., Desai, J., Solomon, B. J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M. J., Cha, E., Bang, Y.-J., Siu, L. L., & Bendell, J.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Asan Medical Center (KR)
  • National University Cancer Institute, Singapore (SG)
  • Jewish General Hospital (CA)
  • Seoul National University (KR)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • University of Washington (US)
  • Massachusetts General Hospital (US)
  • The Royal Melbourne Hospital (AU)
  • Peter MacCallum Cancer Centre (AU)
  • Roche (Canada) (CA)
  • Genentech (US)
  • University Health Network (CA)
  • Tennessee Oncology (US)
Corresponding author
  • Hellmann, M.D.
  • Foster, P.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-07
Volume
30
Issue
7
Pages
1134-1142
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2929513598
Cited by
174
References
19
Citations by year
2026: 7 · 2025: 14 · 2024: 37 · 2023: 30 · 2022: 26 · 2021: 39 · 2020: 14 · 2019: 7
FWCI
8.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • F. Hoffmann-La Roche Ltd./Genentech
  • Inc.
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cobimetinib, MEK inhibition, PD-L1 blockade, immune checkpoint blockade, combination immunotherapy, solid tumors, metastatic colorectal cancer, melanoma, non-small cell lung cancer, microsatellite instability, treatment-related adverse events, tumor-infiltrating T cells, dose escalation, safety and tolerability
MeSH terms
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Azetidines, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Piperidines, Prognosis, Tissue Distribution, Survival Rate, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. https://app.cochat.ai/papers/10.1093/annonc/mdz113
The paper
Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., Desai, J., Solomon, B. J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M. J., Cha, E., Bang, Y.-J., . . . Bendell, J. (2019). Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology. https://doi.org/10.1093/annonc/mdz113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.